The JAK2 exon 12 mutations: A comprehensive review

A variety of acquired mutations targeting JAK2 exon 12 are present in those patients with the myeloproliferative neoplasm, polycythemia vera, that lack the more common JAK2V617F mutation. Both mutation types perturb erythropoiesis, with individuals presenting with a raised hematocrit, reduced serum erythropoietin levels, and erythropoietin‐independent erythroid progenitor cells. However, there are also phenotypic differences that, until recently, precluded a significant proportion of patients with a JAK2 exon 12 mutation from receiving an appropriate diagnosis. Here, we review the literature published on the JAK2 exon 12 mutations and compare the biology associated with these mutations with that of JAK2V617F. Am. J. Hematol. 2011. © 2011 Wiley‐Liss, Inc.

[1]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[2]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[3]  M. Cazzola,et al.  Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. , 2011, Blood.

[4]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[5]  M. Cazzola,et al.  The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera , 2009, Leukemia.

[6]  I. Kourtzelis,et al.  Fast and reliable mutation detection of the complete exon 11–15 JAK2 coding region using non‐isotopic RNase cleavage assay (NIRCA) , 2009, European journal of haematology.

[7]  K. Ohyashiki,et al.  Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. , 2009, Japanese journal of clinical oncology.

[8]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[9]  M. McBride,et al.  A population‐based study of childhood myelodysplastic syndrome in British Columbia, Canada , 1999, British journal of haematology.

[10]  P. Chiusolo,et al.  Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms , 2009, American journal of hematology.

[11]  A. Green,et al.  Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. , 2008, The New England journal of medicine.

[12]  Peter J Campbell,et al.  Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. , 2008, Blood.

[13]  D. Birnbaum,et al.  Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.

[14]  M. Cazzola,et al.  A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications , 2010, Leukemia.

[15]  Tai-Sung Lee,et al.  Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations , 2009, BMC Structural Biology.

[16]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[17]  A. Axelrad,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974, The New England journal of medicine.

[18]  R. Kralovics,et al.  Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. , 2008, Blood.

[19]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[20]  T. Haferlach,et al.  Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera , 2009, Haematologica.

[21]  Ashot Harutyunyan,et al.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms , 2009, Nature Genetics.

[22]  A. Huber,et al.  JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera , 2008, Leukemia & lymphoma.

[23]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[24]  G. Tiscia,et al.  A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. , 2007, Blood.

[25]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[26]  Andrew Collins,et al.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.

[27]  J. Johnston,et al.  SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases , 2009, Haematologica.

[28]  D. Steensma,et al.  Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS‐T) a necessary or useful diagnostic category? , 2009, British journal of haematology.

[29]  G. Barosi,et al.  MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. , 2008, Blood.

[30]  A. Green,et al.  Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones , 2009, British journal of haematology.

[31]  A. Tefferi,et al.  Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.

[32]  G. Mufti,et al.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. , 2005, Gastroenterology.

[33]  K. Schwarz,et al.  Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera , 2008, British journal of haematology.

[34]  Prchal Jf,et al.  Letter: Bone-marrow responses in polycythemia vera. , 1974 .

[35]  P. Mannucci,et al.  Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis , 2006, Hepatology.

[36]  P. Campbell,et al.  Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.

[37]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.

[38]  J. Shi,et al.  The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay , 2010, International journal of laboratory hematology.

[39]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[40]  Nicholas C P Cross,et al.  The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. , 2002, Human molecular genetics.

[41]  N. Harris,et al.  No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-cell Lymphoma , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[42]  F. Rodeghiero,et al.  Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: Report of a new mutation , 2009, American journal of hematology.

[43]  A. Green,et al.  Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis , 2008, Haematologica.

[44]  J. Gécz,et al.  Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients , 2008, Leukemia.

[45]  W. Vainchenker,et al.  Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F‐negative polycythaemia vera patients , 2008, British journal of haematology.

[46]  G. Wainreb,et al.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.

[47]  J. Spivak,et al.  Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. , 2007, Experimental hematology.

[48]  S. Chevret,et al.  The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. , 2008, Blood.

[49]  R. V. van Etten,et al.  Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F , 2006, PloS one.

[50]  V. Ugo,et al.  Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients , 2010, PloS one.

[51]  A. Green,et al.  The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels , 2007, Haematologica.

[52]  A. Tichelli,et al.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.

[53]  A. Green,et al.  Molecular genetics and cytogenetics of myeloproliferative disorders. , 1998, Bailliere's clinical haematology.

[54]  F. J. Novo,et al.  Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs. , 2008, Leukemia research.

[55]  B. Bellosillo,et al.  JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis , 2007, Haematologica.

[56]  T. Barbui,et al.  JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations , 2011, Leukemia.

[57]  P. Rothberg,et al.  Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing. , 2010, The Journal of molecular diagnostics : JMD.

[58]  P. Campbell,et al.  The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. , 2010, Blood.

[59]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[60]  A. Giorgetti,et al.  Loss of the JAK2 intramolecular auto‐inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis , 2008, British journal of haematology.

[61]  A. Gratwohl,et al.  The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders , 2008, Haematologica.

[62]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[63]  M. Stratton,et al.  The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. , 2005, Blood.

[64]  A. Tefferi,et al.  Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. , 2010, American journal of clinical pathology.

[65]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[66]  M. Cazzola,et al.  Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. , 2009, Blood.

[67]  A. Reeve,et al.  Genomic diversity correlates with clinical variation in Ph′-negative chronic myeloid leukaemia , 1986, Nature.

[68]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[69]  A. Green,et al.  AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders , 2010, British journal of haematology.

[70]  S. Verstovsek,et al.  JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? , 2006, Leukemia.

[71]  L. Wiedemann,et al.  The novel activation of ABL by fusion to an ets-related gene, TEL. , 1995, Cancer research.

[72]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[73]  A. Green,et al.  Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera , 2007, British journal of haematology.

[74]  W. Vainchenker,et al.  The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. , 2007, Blood.

[75]  I. Rapado,et al.  High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. , 2009, The Journal of molecular diagnostics : JMD.

[76]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[77]  P. Campbell,et al.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[78]  N. Yoo,et al.  Absence of JAK2 Exon 12 Mutation in Acute Leukemias , 2008, Acta Haematologica.

[79]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[80]  K. Inokuchi,et al.  Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia , 2008, Leukemia.

[81]  J. Melo,et al.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.

[82]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[83]  J. Limon,et al.  JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. , 2010, Leukemia research.

[84]  Yi Lin Chen,et al.  High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. , 2010, American journal of clinical pathology.

[85]  A. Green,et al.  7 Molecular genetics and cytogenetics of myeloproliferative disorders , 1998 .

[86]  A. Wilks,et al.  Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase , 1991, Molecular and cellular biology.

[87]  K. Liedl,et al.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.

[88]  T. Pearson.  Evaluation of diagnostic criteria in polycythemia vera. , 2001, Seminars in hematology.

[89]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[90]  M. Kyba,et al.  A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation* , 2009, The Journal of Biological Chemistry.

[91]  R. Silver,et al.  JAK2 Mutations are present in all cases of polycythemia vera , 2008, Leukemia.

[92]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[93]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[94]  H. Kantarjian,et al.  Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. , 2009, The Journal of molecular diagnostics : JMD.

[95]  L. Happerfield,et al.  Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms , 2009, British journal of haematology.

[96]  Erin F. Simonds,et al.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.

[97]  Fabrizio Giordanetto,et al.  Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. , 2002, Protein engineering.

[98]  L. Plank,et al.  A Novel JAK2 Exon 12 Mutation Identified in the Retrospective Analysis of Paraffin-embedded Tissues of Polycythemia Vera Patients , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[99]  Pawel Dobrzanski,et al.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.